Difelikefalin (Kapruvia®). HTA ID: 23001

Assessment Status Full HTA submission received from Applicant
HTA ID 23001
Drug Difelikefalin
Brand Kapruvia®
Indication For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.
Assessment Process
Rapid review commissioned 09/01/2023
Rapid review completed 02/02/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of difelikefalin compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/03/2023
Pre-submission consultation with Applicant 16/05/2023
Full submission received from Applicant 12/09/2023